WOONSOCKET, R.I., June 14 /PRNewswire-FirstCall/ -- MultiCell Technologies, Inc. (OTC Bulletin Board:MCET.ob - News) has retained Clinical Development & Support Services, Ltd. (CDSS) of Cheshire, England to manage its planned Phase IIb clinical trial in the United Kingdom for MCT-125, the Company's lead drug candidate for treatment of primary multiple sclerosis-related fatigue (PMSF).
was active across all multiple sclerosis (MS) disease severity assessment scales, and on patients regardless of MS disease sub-type (primary progressive, secondary progressive and relapsing-remitting).
PMSF comes on suddenly, and is overwhelming in proportion to any activity undertaken. PMSF can severely affect an MS patient's quality of life, ability to function, and ability to feel they have control over their illness. MS patients with PMSF experience an overwhelming tiredness, lack of energy, and a feeling of exhaustion. The causes of fatigue in MS are thought be partly the result of the disease process itself, and partly the result of other factors (secondary fatigue) that affect a person with MS more significantly than people without the disease. PMSF affects over 70% of persons with MS. Pharmacological treatment options for PMSF are limited, and no drug has been specifically approved by the U.S. Food and Drug Administration for the treatment of PMSF.